SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET

Company Participants

Kellen Sanger - Head of Strategy and Investor Relations
Jurgi Camblong - Co-Founder and Chief Executive Officer
George Cardoza - Incoming Chief Financial Officer
Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer

Conference Call Participants

Dan Brennan - TD Cowen
Subbu Nambi - Guggenheim
Conor McNamara - RBC Capital Markets

Operator

Good morning. My name is Nicole [ph] and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter 2024 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Tuesday, November 5, 2024.

I would now like to turn the conference over to Kellen Sanger, SOPHiA GENETICS' Head of Strategy and Investor Relations. Please go ahead.

Kellen Sanger

Thank you and good morning, everyone. Welcome to the SOPHiA GENETICS third quarter 2024 earnings conference call. Joining me today to discuss the results are Dr. Jurgi Camblong, our Co-Founder and Chief Executive Officer; Ross Muken, our Company President; and George Cardoza, our Chief Financial Officer.

I'd like to remind you that management will make statements during this call that are forward-looking statements within the meanings of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release issued by SOPHiA GENETICS today and in the documents and reports filed by SOPHiA GENETICS from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS to non-IFRS measures is included in today's earnings press release which is available on our website.

With that, I'll now turn the call over to Jurgi.

Jurgi Camblong

Thanks, Kevin and good morning, everyone. I will start today by giving a brief update on our Q3 performance which played out largely as expected, as clinical volume reaccelerated and strong cost management resulted in a significant 39% year-over-year improvements to cash burn. I will then highlight the key growth driver over the next several quarters in MSK-ACCESS powered with SOPHiA DDM which continues to attract strong interest from customers across the block. And last, I will conclude with an exciting update in our leadership team as we further position our results for future growth. Ross will close by providing a more detailed update on Q3 performance and outlook for the remainder of the year.